Management to Host Teleconference Same Afternoon at 4:15 PM ET LIVINGSTON, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Milestone Scientific, Inc. (OTC:MLSS) (BULLETIN BOARD: MLSS) , the recognized leader in advanced injection technologies, today reported that it will announce its 2007 second quarter financial and operational results on Wednesday, August 15, 2007. The Company will host a teleconference the same afternoon beginning at 4:15 PM Eastern Time, and invites all interested parties to join management in a discussion regarding the Company's financial performance, corporate progression and other meaningful developments. The conference call can be accessed by dialing toll-free 1-800-219-6110. For those unable to participate at that time, a replay of the teleconference can be accessed domestically by dialing 1-800-405-2236 and enter the passcode 11094938#. The replay will be available for 90 days. About Milestone Scientific, Inc. Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at http://www.milesci.com/. Safe Harbor Statement This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. FOR MORE INFORMATION, PLEASE CONTACT: Elite Financial Communications Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist 407-585-1080 or via email at DATASOURCE: Milestone Scientific, Inc. CONTACT: Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist, +1-407-585-1080, , both of Elite Financial Communications Group, LLC for Milestone Scientific, Inc. Web site: http://www.milesci.com/

Copyright